Takeda fy2020 q3 results demonstrate growth acceleration and continued resilience; full-year management guidance for fy2020 confirmed, forecast raised for free cash flow and reported eps

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tokyo:4502/nyse:tak) (“takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended december 31, 2020). takeda chief financial officer costa saroukos commented: “our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. as a values-based and r&d driven biopharmaceutical company, we r
TAK Ratings Summary
TAK Quant Ranking